Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
Eisai saw its group sales skid in the fiscal year through March 2023 as it faced a decrease in milestone income tied to its cancer med Lenvima (lenvatinib) and a fallback from a one-time licensing gain a year ago for…
To read the full story
Related Article
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
- Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
May 10, 2023
- Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
February 7, 2023
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai’s Q1 Operating Profit Drops 86% on Upfront Payment Receipt in FY2021
August 8, 2022
- Eisai Scores Sales, Profit Growth on Lenvima Boon in FY2021 despite Aduhelm Setback
May 16, 2022
- Eisai Seeks to File Lecanemab in Japan, US, Europe in FY2022: CEO
May 16, 2022
- Eisai Slashes FY2021 Profit Outlook on Aduhelm Woes
May 9, 2022
- Eisai’s April-December Sales Zoom 13.4% on Lenvima Growth Overseas
February 4, 2022
- Eisai’s H1 Sales Rise 14.3% on 4 Global Brands, ADC License Income
November 2, 2021
- Eisai’s Q1 Sales Jump 20% on Growth of 4 Global Brands
August 5, 2021
- Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
May 13, 2021
- Eisai’s April-December Profits Slip on Aggressive Investments
February 4, 2021
- Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
November 6, 2020
- Eisai Shakes Off Price Cut, Coronavirus Blow with Lenvima Growth in Q1
August 4, 2020
BUSINESS
- Argenx Steps Up Japan Hunt for Drug Discovery Seeds
October 7, 2026
- 1 in 4 Epilepsy Patients Dissatisfied with Current Drugs: Survey
October 7, 2026
- Fujifilm Adds Linker-Payload Capacity to Build One-Stop ADC CDMO Service
October 7, 2026
- Asahi Kasei Therapeutics Reports Potential Data Breach Affecting 560,000
October 7, 2026
- Toho Files Objection to Court Block on Takeover Defense Move
October 7, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…